When the incretin hormone glucagon-like peptide-1 (GLP-1) was subsequently shown to account for up to 70% of insulin secretion in response to nutrient intake (2), its potential as a therapeutic target in type 2 diabetes (T2D) was realized. Here, GCG is linked to type 2 diabetes mellitus.